502 related articles for article (PubMed ID: 23895811)
1. The combined use of aspirin, a statin, and blood pressure-lowering agents (polypill components) and the risk of vascular morbidity and mortality in patients with coronary artery disease.
Lafeber M; Spiering W; van der Graaf Y; Nathoe H; Bots ML; Grobbee DE; Visseren FL
Am Heart J; 2013 Aug; 166(2):282-289.e1. PubMed ID: 23895811
[TBL] [Abstract][Full Text] [Related]
2. The combined use of aspirin, a statin, and blood pressure-lowering agents (polypill components) in clinical practice in patients with vascular diseases or type 2 diabetes mellitus.
Lafeber M; Grobbee DE; Spiering W; van der Graaf Y; Bots ML; Visseren FL;
Eur J Prev Cardiol; 2013 Oct; 20(5):771-8. PubMed ID: 22649123
[TBL] [Abstract][Full Text] [Related]
3. Impact of switching from different treatment regimens to a fixed-dose combination pill (polypill) in patients with cardiovascular disease or similarly high risk.
Lafeber M; Spiering W; Visseren FL; Grobbee DE; Bots ML; Stanton A; Patel A; Prabhakaran D; Webster R; Thom S; Rodgers A;
Eur J Prev Cardiol; 2017 Jun; 24(9):951-961. PubMed ID: 28436727
[TBL] [Abstract][Full Text] [Related]
4. The evening versus morning polypill utilization study: the TEMPUS rationale and design.
Lafeber M; Grobbee DE; Bots ML; Thom S; Webster R; Rodgers A; Visseren FL; Spiering W
Eur J Prev Cardiol; 2014 Apr; 21(4):425-33. PubMed ID: 23382539
[TBL] [Abstract][Full Text] [Related]
5. The cardiovascular polypill in high-risk patients.
Lafeber M; Spiering W; Singh K; Guggilla RK; Patil V; Webster R;
Eur J Prev Cardiol; 2012 Dec; 19(6):1234-42. PubMed ID: 22019908
[TBL] [Abstract][Full Text] [Related]
6. Predicting the impact of polypill use in a metabolic syndrome population: an effectiveness and cost-effectiveness analysis.
Zomer E; Owen A; Magliano DJ; Ademi Z; Reid CM; Liew D
Am J Cardiovasc Drugs; 2013 Apr; 13(2):121-8. PubMed ID: 23532687
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of ankle-brachial index and dobutamine stress echocardiography for cardiovascular morbidity and all-cause mortality in patients with peripheral arterial disease.
Thatipelli MR; Pellikka PA; McBane RD; Rooke TW; Rosales GA; Hodge D; Herges RM; Wysokinski WE
J Vasc Surg; 2007 Jul; 46(1):62-70; discussion 70. PubMed ID: 17583463
[TBL] [Abstract][Full Text] [Related]
8. Impact of adding aspirin to beta-blocker and statin in high-risk patients undergoing major vascular surgery.
Lau WC; Froehlich JB; Jewell ES; Montgomery DG; Eng KM; Shields TA; Henke PK; Eagle KA
Ann Vasc Surg; 2013 May; 27(4):537-45. PubMed ID: 23535525
[TBL] [Abstract][Full Text] [Related]
9. Effects of a secondary prevention combination therapy with an aspirin, an ACE inhibitor and a statin on 1-year mortality of patients with acute myocardial infarction treated with a beta-blocker. Support for a polypill approach.
Zeymer U; Jünger C; Zahn R; Bauer T; Bestehorn K; Senges J; Gitt A
Curr Med Res Opin; 2011 Aug; 27(8):1563-70. PubMed ID: 21682553
[TBL] [Abstract][Full Text] [Related]
10. Usefulness of hypertensive blood pressure response during a single-stage exercise test to predict long-term outcome in patients with peripheral arterial disease.
de Liefde II; Hoeks SE; van Gestel YR; Bax JJ; Klein J; van Domburg RT; Poldermans D
Am J Cardiol; 2008 Oct; 102(7):921-6. PubMed ID: 18805123
[TBL] [Abstract][Full Text] [Related]
11. Combined use of polypill components in patients with type 2 diabetes mellitus.
Janssen VE; Visseren FL; de Boer A; Grobbee DE; Westerink J; van der Graaf Y; Lafeber M;
Eur J Prev Cardiol; 2018 Sep; 25(14):1523-1531. PubMed ID: 30033753
[TBL] [Abstract][Full Text] [Related]
12. Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy.
Silva M; Matthews ML; Jarvis C; Nolan NM; Belliveau P; Malloy M; Gandhi P
Clin Ther; 2007 Feb; 29(2):253-60. PubMed ID: 17472818
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of hypotensive blood pressure response during single-stage exercise test on long-term outcome in patients with known or suspected peripheral arterial disease.
de Liefde II; Hoeks SE; van Gestel YR; Klein J; Verhagen HJ; van Domburg RT; Poldermans D
Coron Artery Dis; 2008 Dec; 19(8):603-7. PubMed ID: 19005295
[TBL] [Abstract][Full Text] [Related]
14. The Effect of a Cardiovascular Polypill Strategy on Pill Burden.
Truelove M; Patel A; Bompoint S; Brown A; Cass A; Hillis GS; Peiris D; Rafter N; Reid CM; Rodgers A; Tonkin A; Usherwood T; Webster R;
Cardiovasc Ther; 2015 Dec; 33(6):347-52. PubMed ID: 26280247
[TBL] [Abstract][Full Text] [Related]
15. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk.
Patel A; Cass A; Peiris D; Usherwood T; Brown A; Jan S; Neal B; Hillis GS; Rafter N; Tonkin A; Webster R; Billot L; Bompoint S; Burch C; Burke H; Hayman N; Molanus B; Reid CM; Shiel L; Togni S; Rodgers A;
Eur J Prev Cardiol; 2015 Jul; 22(7):920-30. PubMed ID: 24676715
[TBL] [Abstract][Full Text] [Related]
16. Results of a retrospective database analysis of adherence to statin therapy and risk of nonfatal ischemic heart disease in daily clinical practice in Italy.
Corrao G; Conti V; Merlino L; Catapano AL; Mancia G
Clin Ther; 2010 Feb; 32(2):300-10. PubMed ID: 20206788
[TBL] [Abstract][Full Text] [Related]
17. Prospective meta-analysis of trials comparing fixed dose combination based care with usual care in individuals at high cardiovascular risk: the SPACE Collaboration.
Webster R; Patel A; Billot L; Cass A; Burch C; Neal B; Usherwood T; Thom S; Poulter N; Stanton A; Bots ML; Grobbee DE; Prabhakaran D; Reddy KS; Field J; Bullen C; Elley CR; Selak V; Rafter N; Wadham A; Berwanger O; Rodgers A;
Int J Cardiol; 2013 Dec; 170(1):30-5. PubMed ID: 24144927
[TBL] [Abstract][Full Text] [Related]
18. [The polypill as cardiovascular prophylactic: clinical trials].
Sandli OK; Spigset O; Slørdal L
Tidsskr Nor Laegeforen; 2014 Mar; 134(6):620-3. PubMed ID: 24670510
[TBL] [Abstract][Full Text] [Related]
19. Use of a Multidrug Pill In Reducing cardiovascular Events (UMPIRE): rationale and design of a randomised controlled trial of a cardiovascular preventive polypill-based strategy in India and Europe.
Thom S; Field J; Poulter N; Patel A; Prabhakaran D; Stanton A; Grobbee DE; Bots ML; Reddy KS; Cidambi R; Rodgers A
Eur J Prev Cardiol; 2014 Feb; 21(2):252-61. PubMed ID: 23038750
[TBL] [Abstract][Full Text] [Related]
20. Statin reduces mortality and morbidity in systemic lupus erythematosus patients with hyperlipidemia: A nationwide population-based cohort study.
Yu HH; Chen PC; Yang YH; Wang LC; Lee JH; Lin YT; Chiang BL
Atherosclerosis; 2015 Nov; 243(1):11-8. PubMed ID: 26342937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
